TY - JOUR
T1 - IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a
AU - Ross, Christian
AU - Engler, Claus Bødker
AU - Sander, Birgit
AU - Bendtzen, Klaus
PY - 2002/4/1
Y1 - 2002/4/1
N2 - We tested for development of binding and neutralizing antibodies to interferon-alpha (IFN-alpha) during IFN-alpha2a therapy of patients with age-related macular degeneration (AMD) of the eyes. Antibodies were investigated retrospectively in sera of 34 patients treated with 3 x 10(6) IU IFN-alpha2a (Roceron-A), Hoffmann La-Roche, Basel, Switzerland) three times weekly for periods of 8-16 weeks with or without a drug-free 4-12-week intermission. Additionally, 10 patients were investigated prospectively; 7 received 1.5-6 x 10(6) IU IFN-alpha2a three times weekly for 12 months, and 3 received placebo. Binding antibodies were tested by molecular size and protein G affinity chromatography using 125I-IFN-alpha2a. Neutralizing activities were tested by antiviral neutralization bioassay. IgG antibodies were detected in 24 of 34 IFN-alpha2a-treated patients (71%). Significantly higher anti-IFN-alpha levels were observed in patients who after discontinuation were readministered IFN-alpha2a (p <0.02). Three of the IFN-alpha2a-treated patients in the prospective study had high and 1 had low antibody titers. Neutralizing antibody titers were high against IFN-alpha2a and IFN-alpha2c and low against lymphoblastoid and leukocyte IFN-alpha. Impaired clinical responses were observed in antibody-positive patients (p <0.01). The development of neutralizing anti-IFN-alpha antibodies in patients with AMD during recombinant human IFN-alpha therapy may explain the often poor clinical effect of IFN-alpha treatment.
AB - We tested for development of binding and neutralizing antibodies to interferon-alpha (IFN-alpha) during IFN-alpha2a therapy of patients with age-related macular degeneration (AMD) of the eyes. Antibodies were investigated retrospectively in sera of 34 patients treated with 3 x 10(6) IU IFN-alpha2a (Roceron-A), Hoffmann La-Roche, Basel, Switzerland) three times weekly for periods of 8-16 weeks with or without a drug-free 4-12-week intermission. Additionally, 10 patients were investigated prospectively; 7 received 1.5-6 x 10(6) IU IFN-alpha2a three times weekly for 12 months, and 3 received placebo. Binding antibodies were tested by molecular size and protein G affinity chromatography using 125I-IFN-alpha2a. Neutralizing activities were tested by antiviral neutralization bioassay. IgG antibodies were detected in 24 of 34 IFN-alpha2a-treated patients (71%). Significantly higher anti-IFN-alpha levels were observed in patients who after discontinuation were readministered IFN-alpha2a (p <0.02). Three of the IFN-alpha2a-treated patients in the prospective study had high and 1 had low antibody titers. Neutralizing antibody titers were high against IFN-alpha2a and IFN-alpha2c and low against lymphoblastoid and leukocyte IFN-alpha. Impaired clinical responses were observed in antibody-positive patients (p <0.01). The development of neutralizing anti-IFN-alpha antibodies in patients with AMD during recombinant human IFN-alpha therapy may explain the often poor clinical effect of IFN-alpha treatment.
U2 - 10.1089/10799900252952208
DO - 10.1089/10799900252952208
M3 - Journal article
SN - 1079-9907
VL - 22
SP - 421
EP - 426
JO - Journal of Interferon & Cytokine Research
JF - Journal of Interferon & Cytokine Research
IS - 4
ER -